Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 20 citing articles:

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Cédric S. Tremblay, Jesslyn Saw, Feng Yan, et al.
Leukemia (2025)
Open Access | Times Cited: 1
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
Matteo Molica, Salvatore Perrone, Marco Rossi
Journal of Clinical Medicine (2023) Vol. 12, Iss. 11, pp. 3647-3647
Open Access | Times Cited: 14
Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia
Eitan Kugler, Inbar Cohen, Irina Amitai, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 932-941
Closed Access | Times Cited: 4
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study
Blanca Boluda, Rebeca Rodríguez‐Veiga, Claudia Sargas, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 854-854
Open Access
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian H. Brodermann, et al.
Blood Advances (2024) Vol. 8, Iss. 21, pp. 5590-5597
Open Access | Times Cited: 3
Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials
Yuying Zhao, Xuedi Zhang, Xiaoyan Ding, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies
Gabriele Carullo, Sara Rossi, Valentina Giudice, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 7, pp. 2125-2142
Closed Access | Times Cited: 2
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Tian‐Hua Wei, Zixuan Wang, Meng‐Yi Lu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML Patients
Matteo Molica, Salvatore Perrone, Marco Rossi
(2023)
Open Access | Times Cited: 6
PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia
Yong June Choi, Jaewoo Park, Hyoyi Choi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115066-115066
Open Access | Times Cited: 4
Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
Chun-xiao Hou, Yu Chen, Shan-hao Liu, et al.
Hematology (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 4
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 6, pp. 241-253
Closed Access | Times Cited: 1
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia
Qiang Fu, Yunqi Wang, Hongtao Liu, et al.
Leukemia Research (2024) Vol. 145, pp. 107564-107564
Closed Access | Times Cited: 1
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access | Times Cited: 1
Targeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Cédric S. Tremblay, Jesslyn Saw, Feng Yan, et al.
Research Square (Research Square) (2024)
Open Access
Sustained Remission in an Elderly Patient with Acute Myeloid Leukemia Following Gilteritinib Treatment as Third-Line Salvage Therapy
Matteo Molica
Mediterranean Journal of Hematology and Infectious Diseases (2024) Vol. 16, Iss. 1, pp. e2024079-e2024079
Open Access
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
Monica Messina, Alfonso Piciocchi, Leonardo Maria Siena, et al.
eJHaem (2024) Vol. 5, Iss. 6, pp. 1274-1277
Open Access
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Susana Vives, David Quintela, Mireia Morgades, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4028-4028
Open Access
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
Irene Urbino, Carolina Secreto, Vincenzo Apolito, et al.
Leukemia Research (2023) Vol. 136, pp. 107421-107421
Closed Access | Times Cited: 1
Page 1

Scroll to top